Lipid based particulate formulations for the delivery of antigen.
about
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialAdjuvants: Classification, Modus Operandi, and LicensingCytoplasmic fungal lipases release fungicides from ultra-deformable vesicular drug carriersC-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c miceNasal vaccine innovation.Delivery of foreign antigens by engineered outer membrane vesicle vaccines.Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody.Immunostimulatory colloidal delivery systems for cancer vaccines.Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.Bicontinuous cubic liquid crystals as sustained delivery systems for peptides and proteins.Potential of polymeric nanoparticles in AIDS treatment and prevention.Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept.Oral delivery of nanoparticle-based vaccines.Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids.Overview of Vaccine Adjuvants: Introduction, History, and Current Status.Engraftment of plasma membrane vesicles into liposomes: A new method for designing of liposome-based vaccinesThe role of nanotechnology in the treatment of viral infections.Nanoparticle-Based Mycosis Vaccine.In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.Vaccine adjuvants: smart components to boost the immune system.The role of nanoliposome bilayer composition containing soluble leishmania antigen on maturation and activation of dendritic cells.
P2860
Q24657256-9293D5C8-4B59-4A57-A743-EA3B76C82C4BQ26747586-7DBFFA41-F6DA-432B-A113-3E43D27FF346Q27301805-FCF4A467-B999-485E-B2E0-F0EE5F65C8C3Q28478982-8247759D-7D1E-42A7-B8A9-CCF6AAABEFCDQ30395810-61628882-550D-45BB-BFF6-D9C5FE9CFE09Q33733590-77748F3A-FF2E-411E-B70C-0B88533EFEABQ33819656-C05A6610-2689-4038-BE2D-340AAA36B295Q36452648-BA640BB7-CB06-4048-838E-162CD902AF0CQ36460849-F3C2ED7A-72AE-4296-99DF-5BFB441715C3Q36652638-A8E55324-09DC-4051-801C-3A3351B2AA9BQ36758235-69B818B1-7A65-4D8B-A16B-C2FB89939ED9Q37790711-04B89EDB-D96E-40FB-A55C-BADA2238CCCAQ37818325-C71EA3A0-40F8-4F14-A5CB-7BD768EB2CA4Q37999793-0EEC0AE4-3344-43E4-B1E5-675F6E9C32B5Q38243119-17D4A9C0-2523-4EAB-8569-2879E8EF7B86Q38534493-636EC188-DE43-4EAC-B7E7-57CE0668DCD0Q38813523-4BDE7E47-CF53-4427-92E2-FFCD28CFC5F4Q38904742-7A78E79C-9969-4F4B-8D6B-B7EE3BFF26F4Q40106774-2610A1E1-F9EC-4064-9B21-065D6E48F3E1Q40183778-45719D30-EC4C-484E-AA08-203CC9A7226BQ45080997-A36A6C96-10C8-4D87-907F-B6F7E46CB569Q50063256-0942D974-0311-41D0-8F56-D2BACD099B67Q55270960-D5C39EAB-9F87-428A-B0AF-4B5CC6A72883
P2860
Lipid based particulate formulations for the delivery of antigen.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Lipid based particulate formulations for the delivery of antigen.
@ast
Lipid based particulate formulations for the delivery of antigen.
@en
type
label
Lipid based particulate formulations for the delivery of antigen.
@ast
Lipid based particulate formulations for the delivery of antigen.
@en
prefLabel
Lipid based particulate formulations for the delivery of antigen.
@ast
Lipid based particulate formulations for the delivery of antigen.
@en
P2093
P2860
P1476
Lipid based particulate formulations for the delivery of antigen
@en
P2093
Margaret A Baird
Melissa J Copland
Nigel M Davies
P2860
P304
P356
10.1111/J.1440-1711.2005.01315.X
P50
P577
2005-04-01T00:00:00Z